Robin Foà Selected Research

Residual Neoplasm

5/2024	Management of ALL in adults: 2024 ELN recommendations from a European expert panel.
2/2023	Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases.
1/2023	Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study.
1/2023	Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.
1/2023	High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
1/2021	Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
12/2020	Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
10/2020	Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
1/2020	Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy.
12/2019	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robin Foà Research Topics

Disease

61	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2023 - 08/2002
60	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2023 - 11/2005
34	Neoplasms (Cancer) 04/2023 - 10/2002
31	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/2023 - 12/2009
22	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2024 - 10/2002
19	Residual Neoplasm 05/2024 - 02/2006
18	Leukemia 05/2023 - 10/2002
16	Philadelphia Chromosome 01/2023 - 03/2006
15	Infections 11/2023 - 09/2005
15	Hematologic Neoplasms (Hematological Malignancy) 02/2023 - 12/2005
11	Multiple Myeloma 01/2024 - 08/2006
10	Disease Progression 10/2023 - 11/2007
9	Lymphoma (Lymphomas) 01/2023 - 12/2005
7	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 04/2023 - 01/2017
7	COVID-19 01/2022 - 01/2020
7	Acute Promyelocytic Leukemia 01/2019 - 04/2006
6	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 02/2023 - 05/2007
6	Primary Myelofibrosis (Myelosclerosis) 08/2021 - 07/2010
5	Thrombosis (Thrombus) 01/2022 - 10/2007
5	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2013 - 03/2003
4	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 04/2020 - 07/2004
4	Neutropenia 11/2017 - 09/2005
3	Hypertension (High Blood Pressure) 01/2023 - 01/2019
3	Exanthema (Rash) 01/2022 - 10/2015
3	Hemorrhage 01/2022 - 03/2014
3	Febrile Neutropenia 10/2021 - 05/2014
3	Hairy Cell Leukemia 01/2021 - 01/2012
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2020 - 10/2017
3	Splenomegaly 10/2020 - 03/2014
3	Venous Thromboembolism 01/2020 - 11/2007
3	Anemia 01/2019 - 08/2006
3	Thrombocytopenia (Thrombopenia) 11/2017 - 11/2007
3	Pathologic Complete Response 07/2010 - 06/2005
2	Lymphadenopathy 12/2023 - 02/2012
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2023 - 06/2021
2	Myocardial Ischemia (Ischemic Heart Diseases) 01/2023 - 12/2009

Drug/Important Bio-Agent (IBA)

26	Tyrosine Kinase InhibitorsIBA 01/2023 - 11/2008
24	Rituximab (Mabthera)FDA Link 01/2023 - 08/2007
20	ibrutinibIBA 12/2023 - 11/2016
16	Imatinib Mesylate (Gleevec)FDA Link 01/2023 - 05/2007
11	fludarabineIBA 01/2023 - 12/2011
9	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2023 - 11/2008
9	Phosphotransferases (Kinase)IBA 01/2021 - 04/2011
9	Bendamustine Hydrochloride FDA Link 01/2021 - 10/2015
8	DNA (Deoxyribonucleic Acid)IBA 02/2023 - 12/2008
8	Dasatinib (BMS 354825)FDA Link 01/2023 - 01/2010
7	nilotinib FDA Link 01/2023 - 01/2019
7	ponatinibIBA 01/2022 - 09/2018
6	blinatumomabIBA 09/2023 - 01/2017
6	ruxolitinibIBA 08/2021 - 04/2019
6	Proteins (Proteins, Gene)FDA Link 10/2015 - 10/2002
5	Immunoglobulins (Immunoglobulin)IBA 12/2020 - 11/2006
5	Lenalidomide (CC 5013)FDA Link 11/2017 - 10/2007
5	RNA (Ribonucleic Acid)IBA 01/2016 - 03/2007
5	Dexamethasone (Maxidex)FDA LinkGeneric 01/2016 - 11/2007
4	idelalisibIBA 12/2023 - 01/2019
4	Oxygen (Dioxygen)IBA 01/2022 - 07/2008
4	obinutuzumabIBA 01/2022 - 01/2018
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2010
4	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2022 - 01/2015
4	Anti-Bacterial Agents (Antibiotics)IBA 10/2021 - 05/2014
4	CytokinesIBA 10/2020 - 12/2005
4	Messenger RNA (mRNA)IBA 01/2020 - 04/2008
4	Clofarabine (Clolar)FDA Link 12/2019 - 10/2009
4	AnticoagulantsIBA 01/2019 - 03/2014
4	Histamine (Histamine Dihydrochloride)FDA Link 01/2018 - 12/2015
4	Interleukin-2 (IL2)IBA 01/2018 - 12/2015
4	MicroRNAs (MicroRNA)IBA 04/2015 - 06/2007
4	LigandsIBA 07/2014 - 10/2007
4	Protein Isoforms (Isoforms)IBA 12/2008 - 03/2003
3	Decitabine FDA Link 05/2024 - 10/2020
3	ChemokinesIBA 01/2024 - 07/2017
3	venetoclaxIBA 12/2023 - 01/2023
3	Cell-Free Nucleic AcidsIBA 02/2023 - 01/2017
3	Chlorambucil (Leukeran)FDA Link 01/2022 - 05/2014
3	SteroidsIBA 01/2022 - 05/2007
3	Azacitidine (5 Azacytidine)FDA Link 10/2020 - 08/2019
3	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2019 - 04/2006
3	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2018 - 10/2012
3	purineIBA 11/2017 - 01/2012
3	Alemtuzumab (Campath)FDA Link 11/2017 - 02/2012
3	Monoclonal AntibodiesIBA 10/2017 - 12/2005
3	AntigensIBA 02/2016 - 03/2007
3	Bortezomib (Velcade)FDA Link 03/2013 - 10/2007
3	Prednisone (Sone)FDA LinkGeneric 03/2013 - 10/2007
3	Transcription Factors (Transcription Factor)IBA 01/2013 - 10/2002
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2012 - 03/2007
3	OligonucleotidesIBA 07/2010 - 01/2006
2	Chimeric Antigen ReceptorsIBA 04/2023 - 01/2021
2	Carnitine (L-Carnitine)FDA LinkGeneric 11/2022 - 10/2015
2	LDL Lipoproteins (beta Lipoproteins)IBA 08/2021 - 01/2020

Therapy/Procedure

53	Therapeutics 04/2023 - 10/2005
29	Drug Therapy (Chemotherapy) 05/2024 - 09/2005
8	Immunotherapy 05/2024 - 12/2015
5	Stem Cell Transplantation 05/2023 - 10/2005
5	Salvage Therapy 01/2020 - 01/2012
4	Hematopoietic Stem Cell Transplantation 01/2021 - 08/2012
4	Radiotherapy 01/2020 - 05/2007
3	Homologous Transplantation 01/2022 - 01/2010
3	Aftercare (After-Treatment) 10/2015 - 04/2009